Cancidas Patent Expiration

Cancidas is a drug owned by Merck And Co Inc. It is protected by 10 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 28, 2017. Details of Cancidas's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6136783

(Pediatric)

Antifungal compositions
Sep, 2017

(7 years ago)

Expired
US5952300

(Pediatric)

Antifungal compositions
Sep, 2017

(7 years ago)

Expired
US6136783 Antifungal compositions
Mar, 2017

(7 years ago)

Expired
US5952300 Antifungal compositions
Mar, 2017

(7 years ago)

Expired
US5514650

(Pediatric)

Aza cyclohexapeptide compounds
Jul, 2015

(9 years ago)

Expired
US5514650 Aza cyclohexapeptide compounds
Jan, 2015

(9 years ago)

Expired
US5378804

(Pediatric)

Aza cyclohexapeptide compounds
Sep, 2013

(11 years ago)

Expired
US5792746

(Pediatric)

Aza cyclohexapeptide compounds
Sep, 2013

(11 years ago)

Expired
US5378804 Aza cyclohexapeptide compounds
Mar, 2013

(11 years ago)

Expired
US5792746 Aza cyclohexapeptide compounds
Mar, 2013

(11 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Cancidas is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cancidas's family patents as well as insights into ongoing legal events on those patents.

Cancidas's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Cancidas's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 28, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Cancidas Generics:

Caspofungin Acetate is the generic name for the brand Cancidas. 6 different companies have already filed for the generic of Cancidas, with Areva Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Cancidas's generic

How can I launch a generic of Cancidas before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Cancidas's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Cancidas's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Cancidas -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
50 mg/vial and 70 mg/vial 26 Jun, 2009 1 28 Mar, 2017 Extinguished

Alternative Brands for Cancidas

Cancidas which is used for treating presumed fungal infections in febrile, neutropenic patients., has several other brand drugs using the same active ingredient (Caspofungin Acetate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Fresenius Kabi Usa
Caspofungin Acetate


Apart from brand drugs containing the same ingredient, some generics have also been filed for Caspofungin Acetate, Cancidas's active ingredient. Check the complete list of approved generic manufacturers for Cancidas





About Cancidas

Cancidas is a drug owned by Merck And Co Inc. It is used for treating presumed fungal infections in febrile, neutropenic patients. Cancidas uses Caspofungin Acetate as an active ingredient. Cancidas was launched by Merck in 2001.

Approval Date:

Cancidas was approved by FDA for market use on 26 January, 2001.

Active Ingredient:

Cancidas uses Caspofungin Acetate as the active ingredient. Check out other Drugs and Companies using Caspofungin Acetate ingredient

Treatment:

Cancidas is used for treating presumed fungal infections in febrile, neutropenic patients.

Dosage:

Cancidas is available in powder form for intravenous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
50MG/VIAL POWDER Prescription INTRAVENOUS
70MG/VIAL POWDER Prescription INTRAVENOUS